STAT+: Hospitals say violence against health workers is surging. Tech companies are stepping in to help
One day in early 2020, just weeks before Philadelphia entered lockdown, Thomas Jefferson University’s public…
Category: STAT+
.jpg)
STAT+: Life scientists’ flight to biotech labs stalls important academic research
Step inside Natasha Sheybani’s office at the University of Virginia, where she runs a bioengineering…
STAT+: UnitedHealth faces class-action lawsuit over algorithmic care denials in Medicare Advantage plans
A class-action lawsuit was filed Tuesday against UnitedHealth Group and a subsidiary alleging that they…
STAT+: New NIH head says government has fallen behind pharma on clinical trials
WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure”…
STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: UnitedHealth pushed employees to follow an algorithm to cut off Medicare patients’ rehab care
The nation’s largest health insurance company pressured its medical staff to cut off payments for…
STAT+: Michigan bill that would pare back pharma liability shied law moves closer to enactment
A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical…
STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a…
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster…
.jpg)
STAT+: Patients loved Carbon Health’s diabetes program. That couldn’t save it
A diabetes diagnosis was not what Jason had in mind when he set out on…
STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients
Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered…
STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial
PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding…
STAT+: Vacancy rate in Boston-area lab space climbs to 10-year high
As Massachusetts biotech companies slash jobs and face dwindling investments, it appears that the long-red-hot real…
STAT+: After decades in use, heart stents finally beat placebo. It took a bold researcher
PHILADELPHIA — A new study, and the bold doctor who led it, could result in…
STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya
And so, another working week will soon draw to a close. Not a moment too…
STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity
LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe…
STAT+: Medicare’s new pay boost for primary care is angering specialists
WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and…
STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Senate panel clears PBM reforms, safety-net hospital payments
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy…
STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research
LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon…
STAT+: FDA approves high blood pressure device from ReCor Medical
The Food and Drug Administration approved a surgical system used to reduce blood pressure from…
STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Biotech incubator Curie.Bio graduates its first startup
Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group…
STAT+: In the fight against cancer, it’s boom times for radiopharmaceuticals
When Ken Song was getting ready to leave his job as the CEO of a…
STAT+: FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19
WASHINGTON — Current and former government officials proffered a clear eyed, and often depressing, take…
STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings
Making good on a recent threat, the U.S. Federal Trade Commission is challenging more than…
STAT+: FTC’s Lina Khan makes a stop at Y Combinator, how telehealth helps rural America
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT+: FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs
After years of trying, the U.S. Food and Drug Administration is again seeking to withdraw…
STAT+: Drug shortages and the supply chain are a matter of national security, experts say
WASHINGTON – The pandemic showed how fragile the supply chain can be, and to fix…
STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Remote patient monitoring helped manage hypertension better, but at a higher cost
During the pandemic, in search of tools to keep patients healthy and virus-free, doctors turned…
Opinion: STAT+: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint
In August 2013, the FDA made news when it issued cybersecurity guidance for medical devices….
STAT+: Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug
SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an…
STAT+: Data backing prescription digital therapeutics found lacking in rigor, inclusivity
The fast-evolving world of digital therapeutics offers the promise of lowering barriers to accessing health…
STAT+: Government looks to tinker with new caps on Medicare Advantage broker payments
The federal government is proposing to rein in health insurance companies that entice brokers with…
STAT+: HHS secretaries Becerra, Azar face off on lowering drug prices
WASHINGTON — Two very different health secretaries took the stage Monday to defend their presidents’…
STAT+: Moonlake’s credibility takes another hit with mid-stage study spin job
Moonlake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…
In experiment, electrical stimulation of the spinal cord helps a patient with Parkinson’s to walk
An experimental treatment that delivers an electrical current to the spinal cord appeared to notably…
STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor
Astellas on Saturday presented study results showing an increased treatment effect over time for its…
STAT+: Medicare moves ahead with more price transparency requirements for hospitals
The federal government is moving forward with a spate of proposals that will force hospitals…
STAT+: Democrats push government to police algorithms in Medicare Advantage
House Democrats are raising concerns with the Biden administration that Medicare Advantage plans need better…
STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds
Most of the formularies run by some of the largest health plans in the U.S….
STAT+: Medicare proceeds with plan to claw back hospital funds after Supreme Court decision
WASHINGTON — Medicare officials are moving forward with a plan to claw back money from certain…
STAT+: Key Senate panel to consider PBM, drug pricing reform package
WASHINGTON — A key Senate panel announced it will consider more policies to regulate pharmacy…
STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy
To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large…
STAT+: Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates
A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising…
STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….